

Utah State University

DigitalCommons@USU

---

Research on Capitol Hill

Browse Undergraduate Research Events

---

2017

## Structural and Functional Characterization of the *Shigella flexneri* Type Three Secretion System (T3SS) ATPase Spa47

Jenna Bouvang

Follow this and additional works at: <https://digitalcommons.usu.edu/roch>

---

### Recommended Citation

Bouvang, Jenna, "Structural and Functional Characterization of the *Shigella flexneri* Type Three Secretion System (T3SS) ATPase Spa47" (2017). *Research on Capitol Hill*. Paper 61.

<https://digitalcommons.usu.edu/roch/61>

This Article is brought to you for free and open access by the Browse Undergraduate Research Events at DigitalCommons@USU. It has been accepted for inclusion in Research on Capitol Hill by an authorized administrator of DigitalCommons@USU. For more information, please contact [digitalcommons@usu.edu](mailto:digitalcommons@usu.edu).



# Unraveling the Driving Forces Behind Bacterial Infection

Jenna Bouvang, Utah State University | Dr. Nicholas Dickenson, Utah State University

## Introduction

*Shigella flexneri* is a water-borne Gram-negative bacterial pathogen which causes shigellosis, a severe form of dysentery that is hallmarked by massive fluid loss and hemorrhaging of the intestines. *Shigella* is responsible for a least 90 million infections and more than 100,000 deaths per year. The recent emergence of multidrug-resistant *Shigella* strains underscores the need for alternative treatment options which can only be achieved with a better understanding of the means by which *Shigella* infects human cells.

*Shigella* relies on a Type Three Secretion System (T3SS) to inject proteins into host cells and ultimately cause infection. We recently identified the T3SS protein Spa47 as an enzyme that provides the energy for protein secretion. Here we solved the crystal structure of Spa47, generated and activated oligomeric model, and identified key amino acid residues necessary for T3SS function and *Shigella* infection.

Study conducted with funding from a USU Undergraduate Research and Creative Opportunity Grant and with funding from grants from the National Institutes of Health (1K22AI099086-01A1) and The National Science Foundation (1530862).



Jenna Bouvang  
Utah State University  
Department of Chemistry & Biochemistry  
jenna.hawley@aggiemail.usu.edu


## Methods

- A series of Spa47 mutants were cloned, expressed, and purified.
- The activity of each of these mutants were measured using a radioactive ATP hydrolysis activity assay
- The Spa47<sup>Δ1-79</sup> mutant was crystallized and the structure was determined using X-ray diffraction.
- A complete series of phenotypic studies were performed to determine the role of Spa47 activation in *Shigella* infection.

## Results


- The first crystal structure of Spa47 was solved and used to generate an activated Spa47 model (see Figure 1).
- Each of the mutations resulted in an elimination of ATP hydrolysis activity.
- *Shigella* harboring the inactive Spa47 mutations could not infect host cells.
- The loss of infection capabilities resulted from the inability of *Shigella* to assemble a proper T3SS apparatus.

**Figure 1** – Cartoon depiction of the *Shigella* T3SA, the solved structure of Spa47, and our model of activated Spa47



Burgess, J.L., Burgess, R.A., Morales, Y., Bouvang, J.M., Johnson, S.J., Dickenson N.E. (2016) Structural and Biochemical Characterization of Spa47 Provides Mechanistic Insight into Type III Secretion System ATPase Activation and *Shigella* Virulence Regulation *J.Biol. Chem.* **291**.

**Figure 2** – Effects of engineered Spa47 mutations on *Shigella* infection



## Conclusions

ATPases play a critical role in the energetics and regulation of T3SS infection-mediated bacterial infections. This first structure-function characterization of Spa47 provides critical insight into the regulation of *Shigella* infection which clearly requires Spa47 oligomerization to activate the enzyme. It is our hope that these and future studies will support the development of much needed non-antibiotic based treatments for shigellosis and other related diseases.